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Abstract 
Ceramide is a sphingolipid second messenger that is 
involved in apoptosis and other cellular responses to 
stress. Ceramide generation occurs primarily by two 
methods: hydrolysis of sphingomyelin by sphingomyelinases or 
by de novo synthesis, which is initiated on the surface of 
the endoplasmic reticulum by serine palmitoyltransferase 
(SPT). The de novo synthesis of ceramide is activated in 
response to' retinoic acid, chemotherapeutic agents like 
etoposide or daunorubicin, and TNF- . We have shown 
previously that SPT is activated in response to chemotherapy 
~ 
and governs de novo ceramide production. To determine 
factors that regulate SPT and the de novo pathway we have 
investigated this pathway in cells over-expressing Bcl-2. 
Bcl-2 is a 26-kDa integral membrane oncoprotein that is 
capable of suppressing apoptosis. It prevents many of the 
morphological and biochemical changes observed in apoptosis. 
It was shown that Bcl-2 interrupts apoptosis by different 
mechanisms such as forming heterodimers with Bax, affecting 
Ca+2 flux, or preventing the release from the mitochondria of 
apoptotic activators like cytochrome c and AIF. We herein 
demonstrate a caspase-dependent induction of de novo 
ceramide in etoposide-induced apoptosis and its inhibition 
by Bcl-2. 
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Sphingolipids are a diverse group of compounds that 
differ from glycerolipids in having a sphingoid base 
instead of glycerol as the cornman structural component 
(figure 1). Structurally, the most basic sphingolipids are 
the sphingoid or long-chain bases (lcb) sphinganine and 
sphingosine. These can be acylated through their amino 
group to produce dihydrocerarnide or ceramide, respectively. 
Fina~ly, the complex sphingolipids are formed by the 
addition of polar head groups to ceramide. 
The key sites on sphingolipid molecules are located on 
carbons 1-5 of the sphingoid backbone. These functional 
groups confer on sphingolipids their important biological 
functions and specificity. C-1 and C-3 are the locations of 
hydroxyl groups and the C-3 hydroxyl group serves as the 
site for polar headgroup addition. C-2 is the site of the 
amino group through which the fatty acid is attached, and 
C-4/C-5 is the location of the trans double bond, which 
confers specificity_ Importantly, dihydroceramide which 
differs from ceramide only in that it is fully saturated at 
C-4/C-5 is without signaling function in all the systems 
tested (£igure 1) . 
1 
Ceramide generation 
Ceramide can be generated from three sources. One of 
~ 
these is by sphingomyelin hydrolysis, which was the first 
route identified for generation of a signaling pool of 
ceramide. A second source of ceramide generation is through 
the de novo pathway which has long been known to provide 
substrates for complex sphingolipids biosynthesis and in 
recent years has been observed to supply its own signaling 
pool of ceramide. The third source of ceramide is the 
salvage pathway in which sphingosine from catabolic 
processes is reacylated to form ceramide (reference 5). 
Ceramide fate 
After ceramide is generated from the de novo pathway, 
it can be subject to a number of metabolic modifications. 
Some of the simplest of these include phosphorylation of 
the C-1 hydroxyl group to produce ceramide-l-phosphate or, 
alternatively, acylation at the same position to produce 1-
O-acylceramide. Both of these are metabolic routes that 
have not been shown to be quantitatively significant. 
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Other more quantitatively important modifications of the 1-
OH group include the addition of a phosphorylcholine 
headgroup to yield sphingomyelin or the addition of glucose 
to yield glucosylceramide. A final important metabolic 
route is the catabolism of ceramide by ceramidase to from a 
free fatty acid and sphingoid base (reference 6). 
De novo biosynthesis (Figure 2) 
In our laboratory we focused our attention on the de 
novo pathway with special interest in its regulator~ and 
modulators. The enzymes of the de novo pathway are oriented 
on the cytosolic face of the endoplasmic reticulum (ER) as 
shown by Mandon et al (reference 7) in 1992. The pathway 
starts with the condensation of serine and palmitoyl eoA 
resulting in an 18 carbon sphingoid backbone. This initial 
reaction is mediated by serine palmitoyl transferase (SPT), 
which will be discussed in more detail later. The product 
of this condensation reaction is 3-ketosphinganine, which 
undergoes reduction by ketosphinganine reductase to yield 
sphinganine (dihydrosphingosine) which is, in turn, 
acylated by ceramide synthase (dihydroceramide synthase) to 
give dihydroceramide. Finally, the double bond is added by 
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dihydroceramide desaturase to yield ceramide. So the de 
novo biosynthesis can be summarized in three stages: the 
synthesis of a long-chain base, the formation of ceramide 
by N-acylation, and finally, the transport of ceramide to 
the Golgi for headgroup addition. 
Why is the de novo pathway important? 
The short answer to the above question is because it 
is an important source of ceramide. Ceramide is implicated 
in different cell functions like proliferation, cell cycle 
regulation, senescence, and apoptosis. For all these 
reasons de novo biosynthesis is vital for cellular 
functions in signaling. It is also an essential pathway 
since sphingoid bases are required for cell growth although 
it's unclear if ~his is related to a signaling or 
structural integrity event. Finally, because the de novo 
pathway is involved in generating signaling molecules that 
program cellular events, it is implied that the pathway has 
tightly controlled regulatory mechanisms. 
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Apoptosis 
A- Chemotherapy induced apoptosis (reference 9 for more 
review) 
De novo ceramide synthesis can induce apoptosis in response 
to different chemotherapeutic agents. Etoposide can 
activate apoptosis via de novo ceramide synthesis in Molt-4 
human T-Ieukemia cells (reference 8). This was through SPT 
activation through post-translational modulation since SPT 
mRNA levels did not change. Also, daunorubicin in the P388 
murine leukemia cell line and U937 human monoblastic 
leukemia cells induced the de novo pathway and programmed 
cell death by activating dihydrocerarnide synthase 
(reference 10). This conduct was not limited to 
hematological cancers but also included many of the solid 
tumors cell lines; camptothecin in 4Bl (also called L929) 
mouse fibroblasts, taxol in MCF-7 breast cancer cells, and 
gerncitabine in A549 lung cancer cell line (references 11-
13) . 
It should be noted that induction of de novo ceramide does 
not obligate an apoptotic response. Akao et al (reference 
14) demonstrated this when they treated LNCaP prostate 
cancer cells with camptothecin (CPT-II). Here the cell 
death caused by CPT-II was not because of increased de novo 
ceramide generation. De novo ceramide is synergistic to 
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radiation therapy as is the case when treating LNCaP cells 
with 12-0-tetradecanoylphorbol acetate (TPA) or radiation. 
Neither agent induced apoptosis alone (reference 15). 
The cerarnide-induced apoptosis is gaining more attention 
because of new challenges to old notions regarding how 
chemotherapy induces programmed cell death. It was shown in 
murine mammary cell lines that cell cycle arrest and 
apoptosis caused by taxol are not synonymous processes 
(reference 12). Similar doubts were also cast on 
daunorubicin-induced apoptosis mechanisms because it was 
shown that apoptosis could be induced under conditions 
where no free drug is available intra-cellularly (re';ference 
16) . 
B-Fatty acids induced apoptosis 
Research has shown that de novo synthesis induced apoptosis 
can be activated by applying fatty acids like palmitate or 
stearate directly or by creating conditions that increase 
their availability to the de novo pathway by means of 
inhibiting beta-oxidation with agents like etomoxir that 
inhibits carnitine palmitoyltransferase (CPT-I) (reference 
17). This data was further substantiated using reverse 
methodology by Shimabukuro et al (reference 11). They were 
able to inhibit apoptosis by inhibiting fatty acyl-CoA 
6 
, 
synthase or enhancing free fatty acids beta-oxidation using 
triacsin C or troglitazone, respectively. 
C-Retinoic acid (RAJ induced apoptosis 
PCC7 teratocarcinoma cell line responds to all-trans RA by 
differentiation and apoptosis. In this system, retinoic 
acid activated SPT leading to an increase in de novo 
ceramide generation (reference 19). Treating the GH4C1 rat 
pituitary cell line with all-trans RA also induced de novo 
ceramide but through increasing sphingosine N-acylation 
(reference 20). Other RA derivatives like the synthetic RA, 
N- (4-Hydroxyphenyl) retinamide (4-HPR) produce a similar 
response in CHL90 neuroblastoma cells by activating both 
SPT and dihydroceramide synthase (reference 21). 
D- Cytokines induced apoptosis 
TNF-alpha induced cell death alone or with cycloheximide 
aid in MCF-7 or bovine cerebral endothelial cell line 
(BCECs) cells respectively. In both cases this induced 
apoptosis was through activating the de novo synthesis 
pathway (references 74 and 75). In MCF-7 cells 
sphingomyelin hydrolysis was also activated. 
E- BcR cross linking in B-cells 
In the Ramos cell line (Epstein-Barr negative Burkitt's 
lymphoma cells) BcR cross-linking induced cell death via 
activating de novo ceramide generation (reference 22) 
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F- Cannabinoid-mediated apoptosis 
Both tetrahydrocannabinol (THC) and the CB2 selective 
-
agonist JWH-133 increased de novo ceramide synthesis 
causing cell death in glioma cells (references 24 and 25) . 
It is apparent from all of the data collected that 
different stress agents can induce de novo ·ceramide in a 
variety of systems and the consequence of this induction is 
often apoptosis. 
The nervous system 
It is estimated that about 20-80% of neurons die during 
brain development. This is due to the neurotrophic s~rategy 
where excess neurons are made to maximize enervation 
capacity, then, those without synaptic connections expire 
(reference 19). Ceramide from both de novo and 
sphingomyelin hydrolysis has been implicated in nervous 
system apoptosis. De novo biosynthesis is also involved in 
neuronal differentiation, which was shown by retinoic acid 
experiments in PCC7-Mz1 teratocarcinoma or Neuro2a 
neuroblastoma cell lines (references 19 and 26). There is 
mounting evidence exhibiting clear involvement of de novo 
ceramide synthesis in nervous system pathology. This 
includes a wide range of diseases like neurodegenerative 
etiology. This is the case of Batten's disease where 
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photoreceptors die by programmed cell death (reference 27). 
It was found by Rylova et al that the gene responsible for 
the disease, CLN3 is a negative regulator of de novo 
ceramide biosynthesis (reference 28). De novo ceramide in 
the nervous system is an important factor in other 
pathological processes like the inflammatory process in 
response to cytokines like TNF-alpha (reference 74) and 
cannabinoid mediated effects through their CBl or CB2 
receptors (reference 24). More interesting are the new 
reports identifying 8PT mutations as the culprit in 
hereditary sensory neuropathy type 1 (references 29 and 
30). This is considered the first pathology of sphingolipid 
metabolism that does not involve a lipid storage disease. 
The immune system 
De novo ceramide is responsible for activated induced cell 
death (AICD) in B-cells. This process is believed to 
control B-cell populations and functions to protect the 
body from autoimmune diseases (reference 22). The CB2 
receptor is a cannabinoid receptor that is restricted to 
brain tumors and immune system cells. The CB2 selective 
agonist JWH131 inhibited glioma cell growth by activating 
de novo ceramide. However there may be also a down side for 
ceramide activation by inhibiting the immune system 
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response to malignant cells due to the presence of CB2 
receptors (reference 25). 
Epiderma1 barrier integrity (references 31-33) 
Holleran et ale demonstrated that by disrupting the 
epidermal barrier using chemical, physical or pathological 
methodology, the biosynthesis pathway for sphingolipids is 
activated via inducing SPT activity. The epidermal recovery 
was sequential with an increase in cholesterol first, 
followed by sphingolipids later. Farrell et ale was able to 
show that UVB irradiation will increase SPT activity in 
keratinocytes by up regulating the LCB2 (2.3KB) mRNA 
(reference 33). 
other functions and patho1ogies 
De novo biosynthesis is implicated indirectly in a wide 
range of non-nervous system diseases. This is very clear 
from the occurrence of the harmful effects of fumonisin B 
in humans and animals, which are, associated with an 
increase in the sphingoid base levels in urine and plasma 
samples (references 34 and 35). These diseases include 
equine leukoencephalopathy, porcine pulmonary edema, and 
murine hepatotoxicity. In humans fumonisin B is implicated 
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in endemic esophageal cancer in South Africa (reference 34) 
and endemic nephropathy in Croatia and other parts of 
Eastern Europe (reference 36). The de novo pathway is also 
being implicated in atherosclerosis, obesity and diabetes 
(references 37-39 and 18). Other functions of de novo 
ceramide biosynthesis are cell cycle progression via 
dephosphorylating Rb protein (reference 40), 
serine/arginine-rich (SR) protein phosphorylation which 
regulates alternative splicing (references 13 and 41), and 
modulating drug resistance (reference 42). 
De novo synthesis modulators 
Inhibitors 
1) SPT inhibitors: myriocin, beta-chIaro-alanine, beta-
fluoro-alanine, and L-cycloserine. Sphingoid bases or 
their homologues are also important inhibitors for de 
novo sphingolipid biosynthesis, and may play an 
important role in the endogenous regulation of SPT 
activity and sphingolipid biosynthesis. The sphingoid 
base inhibition effect is dose-and time dependent, SPT 
specific, and stereo specific (references 43-45). The 
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full-length wild type leptin receptor (OB-Rb) also 
inhibits SPT activity (reference 39). 
2) Dihydroceramide synthase (N-acylsphingosine 
transferase) inhibitors: 
Fumonisin B compounds are the most widely known and 
they inhibit dihydroceramide synthase by competitive 
inhibition with its substrates. As shown in (figure 3) 
(reference 35) there is a great resemblance of 
fumonisin B to the sphingoid bases. Fumonisin B can 
inhibit both the salvage pathway as well as the de novo 
by blocking N-acylation of sphingosine and sphinganine. 
~ 
3) Indirect inhibition of de novo ceramide can be 
achieved through manipulating fatty acid oxidation or 
by regulating enzymes that degrade the de novo 
synthesis metabolites. This regulation occurs with 1-
methylthiodihydroceramide (l-MSDH-cer) which inhibits 
de novo synthesis by activating sphinganine kinase, 
leading to degradation of sphinganine (reference 46). 
Activators 
1) SPT activators include; chemotherapeutic agents like 
etoposide, all-trans retinoic acid or synthetic 
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retinoid like 4-HPR, UV irradiation, and fatty acids 
(references 8, 18-21, and 33) . 
2) Dihydroceramide synthase activators: daunorubicin, 4-
HPR, and TPA (references 10, 21, 15, and 47). 
Paradox and comp1exity in studying ceramide 
The study of ceramide is at times complicated by 
contradictory results. These difficulties are due to 
specificity in sphingolipid functions. This specificity can 
be system directed, agent specific, or related to the cell 
status like maturity or differentiation. This applies to 
ceramide generated from sphingomyelin or de novo pathways. 
Since our interest here is de novo we will use examples 
related to the de novo pathway. First, LNCaP prostate 
cancer cells are sensitive to TPA in the confluent status 
but resistant in the plateau phase (references 47 and 15). 
The second example is that mature Ramos B-Iymphoma cells 
respond to BcR cross-linking differently from immature 
WEH231 murine B-Iymphoma cell line (references 22 and 23). 
Third, the PCC7 teratocarcinoma response to all-trans 
retinoic acid is dependent on differentiation status 
(reference 19). Fourth, agent specificity: while etoposide 
induced de novo via SPT activation in Molt-4 human T-
leukemia cell line, other agents like GW 1843 (reference 
13 
50) induced a sphingomyelin source of ceramide. Fifth, is 
dose and time differences; this is evident in the case of 
daunorubicin and the U937 human leukemia cell line 
(references 10 and 16). Bose et ale was able to induce de 
novo ceramide by activating dihydroceramide synthase 
(reference 10) while Jaffrezou showed neutral 
sphingomyelinase activation (reference 16). It should be 
noted that Bose et ale applied 10 micro molar daunorubicin 
for 12 hours and Jaffrezou used only 1 micro molar for 4 
hours. 
Bc1-2 Oncogene 
Bcl-2 was first identified at the chromosomal 
breakpoint of t (14; 18) in human B-cell lymphomas. This 
translocation brings the Bcl-2 gene under the control of 
the actively transcribed 19 gene on chromosome 14. The Bcl-
2 family now includes pro-apoptotic proteins like BAX, BAD, 
and BID, as well as anti-apoptotic members like Bcl-2 and 
Bel-XL (reference 51). The anti-apoptotic members are found 
in the mitochondrial, endoplasmic reticulum and nuclear 
membranes, while the pro-apoptotic are located in the 
cytosol or cytoskeleton. All the anti-apoptotic members are 
composed of four Bcl-2 homology (BH) domains, BH1-BH4, with 
the carboxy-terminal the hydrophobic domain that anchors 
them to the membranes (reference 52). The various methods 
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used to execute their anti- or pro-apoptotic functions 
include: channel forming, homo- or hetero-dimerization, or 
binding to proteins that are involved in programmed cell 
death (reference 53). In the case of Bcl-2 it prevents 
cytochrome c release and inhibits poly (ADP-ribose) 
polymerase (PARP) protease activation (reference 54 and 
55). Bcl-2 was also found to interrupt downstream the 
ceramide pathway in apoptosis without interfering with its 
generation (references 56-58). 
Serine Palmitoyltransferase 
The 8PT enzyme is the rate-limiting enzyme that catalyzes 
the first step in sphingolipid biosynthesis. Most of SPT 
activity is localized to the microsomal fraction (reference 
61). SPT enzyme belongs to a subfamily of the pyridoxa15'-
phosphate utilizing enzymes. This subfamily is called the 
alpha-oxoamine synthases, which catalyze the transfer of 
the acyl group from an acyl-CoA to the alpha-carbon of an 
amino acid. 
In mammalian cells the SPT enzyme consists of two subunits, 
LeB1 and LCB2, with. stoichiometry of 1:1 (reference 62). 
Both LeB1 and.LCB2 'subunits are required for SPT activity 
(references 63 and 64). However, Weiss and Stoffel 
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demonstrated that in human embryonic kidney cells (HEK 293) 
the over expression of LCB2 increases SPT activity 
(reference 65). According to Hanada this might be due to 
forming complexes between the endogenous LCB1 and the over 
expressed LCB2 (reference 63). In yeast SPT is necessary 
for growth (references 66-68). Activity also requires both 
LCBl and LCB2 subunits (references 68-70). Dunn et ale 
isolated an 80-amino acid protein (Tsc3p) that may be part 
of the SPT complex in yeast (reference 71). 
In eukaryotes the SPT subunits are hydrophobic, membrane-
associated proteins with potential transmembrane helices, 
while in bacteria the SPT enzyme is a water-soluble 
homodimeric protein (reference 72). Although it was first 
identified in the late sixties, SPT has been gaining 
renewed interest due to its implication signaling and human 
disease. Nicholson et ale (reference 30) observed mutations 
in SPT of patients with hereditary sensory neuropathy type 
I and postulated that these cause an increase in SPT 
activity leading to the production of more de novo 
ceramide. Predicting this will lead to neural degeneration 
and more apoptosis. However, the r~~ent paper by Dunn et 
ale (reference 73) showed that similar mutations in yeast 
have inhibitory effect on SPT. This discovery will 
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represent more challenges to researchers and further the 
impetus for studying SPT. 
Others and we have demonstrated that cellular stress agents 
can activate SPT and lead to upregulation of de novo 
ceramide and apoptotic responses. We also know that these 
agents due not interact directly with SPT. Therefore, we 
were interested in identifying endogenous upstream 
regulators of SPT in the de novo pathway. 
One lead came from earlier data demonstrating the integral 
relationship between ceramide, caspases, and bcl-2 
(reference 58). This work demonstrated that although bcl-2 
prevents apoptosis and the activation of executioner 
caspases, it does not interfere with ceramide production 
from agents that turn on sphingomyelinase activation. As de 
novo cerarnide production differs spatially in the cell from 
that produced by sphingomyelinases, we set out to determine 
if bcl-2 was capable of regulating de novo ceramide 
production and if caspases were involved in this process. 
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Materia1s and Methods 
Materials: ceramide standards were purchased from 
Avanti polar lipids. [Gamma- 32 P]ATP (3000 Ci/mmol) and [9, 
10_3HJ palmitic acid (43 Ci/mmol] were purchased from NEN. 
Etoposide was purchased from sigma, and z-VAD.fmk peptide 
from Calbiochem. GW 554869a was obtained from Dr. Yusuf 
Hannun's lab. 
Cell culture: Molt-4 T-leukemia cells from Zhang et al 
were used for experiments (reference 57). These cells had 
been transfected with pMEP4 vector with and withou~ 
full- length murine bcl-2. Cells were maintained at 37°C 
and 5% C02 in RPMI medium with 10% fetal calf serum (FeS). 
Ceramide mass measurements: Molt-4 cells were seeded 
at 5x105 /ml in a 6-well plate (3mls/well). After the desired 
treatment, ceramide mass was determined using the 
diglyceride kinase assay (DGK) as (reference76). In summary 
5x105 cells (equals 1 ml and 2 mls left for lipid phosphate 
determination) were used for the DGK assay. These cells 
were lysed in a mixture of chloroform and methanol (1:2) 
and lipids were extracted as prescribed by the Bligh and 
Dyer method (reference 77) then solubilized in mixed 
micelles for 30 minutes at 37°C. Three _9 of membranes from 
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E.coli overexpressing DGK followed by the addition of three 
pCi of [gamrna- 32p] ATP in the presence of 1mM carrier ATP 
and kept at room temperature. Thirty minutes later the 
reaction was quenched with chloroform/methanol (1:2) and 
the lipids extracted again based on the Bligh and Dyer 
method. The chloroform was evaporated and the lipid pellet 
was suspended in 40 I of chloroform/ methanol (4:1) and 
resolved on TLC plates. The solvent system used was 
chloroform/acetone/methanol/acetic acid/water (10:4:3:2:1). 
After autoradiography, the ceramide location was identified 
by iodine-staining of a ceramide standard and radioactivity 
was quantified by liquid scintillation spectrometry. 
Ceramide mass was quantified based on the standard curve 
and normalized to lipid phosphate. 
Lipid phosphate determination: Lipids extracted from 
10 6 Molt-4 cells were concentrated to remove the chloroform. 
Then the lipid pellets were incubated at 180°C overnight in 
0.6 ml of 10 N H2S04/70%HCI04/H20 (9:1:40). Then, 0.6 ml of 
H20, 0.5 ml of 0.9% ammonium molybdate, and 0.2 ml of 9.0% 
freshly made ascorbic acid were added and incubated for 30 
minutes at 45°C. Inorganic phosphate was detected by 
absorbance at 820 nm and quantified based upon a standard 
curve of K2HP04. 
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Radiolabeling of cells: Molt-4 cells were seeded at 
5xl05 /ml (3mls/well in a 6-well plate). 1 _Ci/ml of [3H] 
palmitate was added with 10 micromolar of etoposide at the 
same time. At the desired time point cells were lysed in a 
mixture of chloroform and methanol (1:2) and lipids were 
extracted according to the Bligh and Dyer method. The 
chloroform phase was evaporated in a speed vacuum device 
and the lipid pellets were suspended in 40 I of 
chloroform/methanol (4:1) and resolved on TLC plate. The 
solvent system used was chloroform/methanol/2N NH 40H 
(40:10:1). After chromatography, the ceramide standard was 
identified using iodine vapors. Then, TLC plates were 
sprayed with enhancer, and radioactivity was visualized by 
autoradiography after 48-72 hours at -80°C. The radioactive 
spots corresponding to the ceramide standard were scraped 
and quantified by liquid scintillation spectrometry. 
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Results and discussion 
Our investigations were predicted on data we had previously 
established showing that the topoisomerase inhibitor and 
chemotherapy agent etoposide caused a several-fold 
elevation of ceramide mass in Molt-4 cells (Figure 10) . 
Importantly, it was also demonstrated that the 
dihydroceramide synthase inhibitor, fumonisin, inhibited 
this increase in ceramide suggesting its generation from 
the de novo pathway (reference 8). The involvement of de 
novo ceramide synthesis was further substantiated by 
showing that etoposide indirectly activated the rate-
limiting enzyme in the pathway, serine palmitoyltransferase 
(reference 8). 
As a starting point in looking for upstream regulators of 
de novo ceramide production and for reasons we stated at 
the conclusion of the introductory section, we proceeded to 
utilize Molt-4 cells transfected with a control vector or 
vector containing the murine bcl-2 oncogene. Overexpression 
of murine bcl-2 predominantly in a heavy membrane fraction 
in these cells had earlier been confirmed (reference 57). 
Upon treatment of both cell lines with etoposide over a 12-
hour time course, we observed near total abatement of the 
ceramide response in the bcl-2 over-expressing cells 
compared to the vector control cells (figure 4) . 
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Importantly, ceramide mass was not diminished by an 
inhibitor of the neutral sphingomyelinases implicated in 
ceramide generation in apoptotic signaling. A Glaxo 
Wellcome (G.W) compound inhibits this enzyme and TNF-
signaling responses (reference 79). It was without effect 
in our cells (figure 6) providing further support that 
etoposide-induced ceramide is from the de novo pathway. 
We also investigated the impact of bcl-2 on ceramide 
generation as assessed by a [3H]-palmitate pulse-labeling 
study. Palmitate is rapidly incorporated into palmitoyl 
CoA, a substrate for the first enzyme in the de novo 
pathway, and the radiolabel in the fatty acid chain is 
incorporated into the sphingoid backbone. Further 
metabolism in the de novo pathway results in the production 
of ceramide whose degree of radiolabeling we assessed by 
thin layer chromatography and liquid scintillation 
counting. This pulse, rather than equilibrium, approach 
results in radiolabeled ceramide that is reflective of de 
novo synthesis rather than from constitutive or agonist-
induced turn over of sphingomyelin. 
The period of pulse-labeling was begun at the same time of 
etoposide treatment, and over the course of 12 hours, we 
observed a steady increase in ceramide generation up to 
two-fold after 12 hours (figure 5). As we observed in 
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figure 4 with the mass measurements, corresponding 
inhibition in the bcl-2 over-expressing cells was also 
observed in the ceramide radiolabeling assay. 
That bcl-2 inhibited the ceramide response to etoposide as 
assessed by both fumonisin-sensitive mass measurements and 
radiolabel analysis provides added confidence that bcl-2 is 
functioning as a regulator of the de novo pathway. These 
results also differentiate regulation of the de novo and 
sphingomyelinases mediated pathways of ceramide generation 
as ceramide production by the latter is not inhibited by 
bcl-2 (reference 58). 
Bcl-2 is a membrane protein located primarily in the 
mitochondria. It is an established regulator of apoptosis 
and is thought to mediate its inhibitory effects 
predominantly through regulating mitochondria events. In 
this regard, it prevents the release of cytochrome c from 
the mitochondria, subsequent apoptosome formation, and the 
activation of executioner caspases. Because we observed 
inhibition of de novo ceramidesynthesis in bcl-2 
overexpressing cells and because bcl-2 inhibits activation 
of both caspase-9 and downstream executioner caspases, we 
hypothesized that caspases might be involved in up-
regulating de novo synthesis. 
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To test our hypothesis, we treated Molt-4 cells with 
etoposide +/- varying doses of the pancaspase inhibitor, 
zVAD. zVAD inhibited both mass ceramide accumulation 
(figure 7) and radiolabeled ceramide accumulation (figure 
!) in etoposide-treated vector control cells. 
Correspondingly, the diminished increase of ceramide mass 
observed in the Molt-4 bcl-2-transfected cells was not 
affected by zVAD (£igure 9). 
These results allow us to draw several conclusions. First, 
they further implicate the mitochondria as a coordinating 
center for stress response. In this case, the DNA damage 
induced by etoposide is sensed in an unknown manner by the 
mitochondria leading to apoptotic signaling events. In 
instances were bcl-2 is upregulated, it is unclear if the 
mitochondria still sense the damage or if the damage is 
sensed but unable to be acted upon due to the presence of 
bcl-2. Second, the results demonstrate the necessity of 
caspase activation in de novo ceramide synthesis. 
Identification of the caspase(s) involved in this role 
awaits further study and will be assessed using caspase 
isozyme-specific inhibitors. This is crucial because there 
is a growing body of evidence indicating that pan-caspase 
inhibitors like z-VAD-fmk, z-YVAD-frnk, and Z-DEVD-fmk 
inhibit other cysteine proteases like cathepsins 
24 
B,H,L,S,K,F,V,X and C (reference 80). Some of these 
cysteine proteases especially cathepsin B are involved in 
the apoptotic process (references 81-84) which forces us to 
take data from pan caspase inhibitors with caution and 
emphasizes the importance of future caspase isozyme-
specific inhibitor .Third, the results open to discussion 
the role of de novo ceramide in etoposide-signaling. 
Ceramide has been shown in many instances to act further 
upstream in stress signaling and coordinating stress 
responses. The fact that we observe ceramide generation in 
a distal site (on par with the activation of executioner 
caspases) in the dogmatic apoptosis cascade might suggest 
that it is acting in more of an executioner phase. Fourth 
and finally, although we know from prior work that serin~ 
palmitoyltransferase activation in this system drives de 
novo ceramide generation, we do not know if caspase 
activation is necessary for its activation or if it is 
necessary for progression through the de novo pathway 
downstream of serine palmitoyltransferase. 
In conclusion, these results have identified a novel role 
for Bcl-2 in inhibiting apoptotic responses and have 
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Figure 1.Ceramide: demonstrating the resemblances and 
differences among the three molecules: Ceramide, 
dihydroceramide and diacylglycerol (DAG) . DAG and 
ceramide have opposing cellular functions and 
dihydroceramide is an inert molecule. 
Figure 2. The de novo pathway 
Figure 3. Fumonisins: there are significant similarities 
between fumonisins and sphingoid bases and they act as 
competitive inhibitors of dihydroceramide synthase. 
Figure 4. Effects of Bc~-2 on ceramide production:' Molt-4 
cells transfected with Bcl-2 (solid and open circles) 
or control vector (solid and open squares) were 
treated with 10 etoposide (solid symbols) or vehicle 
control (open symbols) for 0-12 hours. At the 
indicated time points, the cells were harvested, and 
ceramide mass was quantified using diglyceride kinase 
assay and normalized to lipid phosphate. The open 
circles or squares are for control BCL-2 or vector 
cells, respectively. 
Figure 5. Effects of Bc~-2 oncogene on de novo ceramide 
production after etoposide treatment: Molt-4 leukemia 
cells transfected with Bcl-2 oncogene (solid circles) 
or control vector (open squares) were treated with 
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10 etoposide and [3H]-palmitate (1_Ci/ml) for 0-12 
hours. At the indicated time interval, cells were 
harvested and [3H]-ceramide quantified. Results 
represent the fold increase in ceramide at each point 
in comparison to time-matched control. 
Figure 6. Sphingomyelinase inhibition using GW 554869a: 
Molt-4 cells transfected with Bcl-2 (scored bars) or 
control vector (solid bars) were treated with 10 
etoposide for 12 hour~. Concurrent with the addition 
of etoposide, GW 554869a using different 
concentrations was added. At hour 12, the cells were 
harvested and ceramide mass was quantified using DGK 
assay. The results were normalized to lipid phosphate. 
Figure 7. Effect of caspase inhibition on etoposide-
induced ceramide: Molt-4 cells transfected with 
control vector were treated in a dose-dependent manner 
with the pancaspase inhibitor N-benzyloxycarbonyl-val-
ala-asp-fluromethylketone (z-VAD) for 30 minutes. 
Then, 10 etoposide was added and cells incubated for 
12 hours before harvesting. Mass ceramide was 
quantified using DGK assay and normalized to lipid 
phosphate. 
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Figure 8. Effect of caspase inhibition on Etoposide-
induced de novo ceramide: Molt-4 cells transfected 
with control vector were treated in a dose dependant 
manner with z-VAD for 30 minutes. Then, 10 __ etoposide 
and [3H]-palmitate (1 Ci/ml) were added simultaneously 
for 12 hours. At the end of 12 hours cells were 
harvested and [3H]-ceramide quantified. 
Figure 9. Effect of Caspase inhibition on eoposide-
induced ceramide in Bc1-2 ce11s: Molt-4 cells 
transfected with Bcl-2 oncogene were treated in a 
dose-dependent manner with z-VAD for 30 minutes. Then, 
10 __ etoposide was added and cells incubated for 12 
hours before harvesting. Mass ceramide was quantified 
using DGK assay and normalized to lipid phosphate. 
Figure 10. T~e course for the induction of de novo 
Synthesis by etoposide: Molt-4 cells were treated for 
0-6 hours with 10 ~M etoposide in the presence (solid 


















































serine CoA +. '. CO 



















rNAD(p)H + 1/2 02 










CH30R CH3 H 
Sphinganine FumonisJn 81 
OH OR 
CH20H CH3 
NH2 CH30R CH3 NH 2 
Sphingosine Fumonisin 82. 
OH OR 
CH 20H CH3 
CH30R CH·3 
4-Hydroxysphinganine Fumonisin 83 
R = eaCH 2 CH(COOH)CH 2 eOOH 
Figure (3) Advances in Lipid research 
-rj -. 30 (JQ 
t:: 
I-t 
~ • BCL-2 cells n 
",-.... • Vector cells A T 
25 - 8- - BGL-2 ~control~ I I ......" f 
-- ~I .... E - - Vector control· Il. 
tn 






GJ - 10 0 
E 
c. 
5 ~ t-t'"- - ... - - - - - _ .... -~ -_ .. -. -.- _ .... ~ 
--------------6:) 
o 



















0 0 0 0 0 
·0 LA 0 U) 





















































-- 0 0 
.. Q 0 0 CO· :0 .... ,... ... .... 0 
lQ N J;Q ,.. an 


























!d salowu/Ja~ SB/OWc/ 
o ,.. o 















o 2 4 6 
hrs 
Figure (10) 
